TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04515628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Specified dose on specified days
Study: NCT00550862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INT-747
Description: Once a day (QD) by mouth (PO)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: INT-747
Description: Once a day (QD) by mouth (PO)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid (URSO)
Description: Stable dose for at least 6 months prior to screening. Dose as prescribed by physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid (URSO)
Description: Stable dose for at least 6 months prior to screening. Dose as prescribed by physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid (URSO)
Description: Stable dose for at least 6 months prior to screening. Dose as prescribed by physician.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ursodeoxycholic Acid (URSO)
Description: Stable dose for at least 6 months prior to screening. Dose as prescribed by physician.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04237558

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal hysterectomy
Description: Vaginal hysterectomy by removal of uterus through vagina in absence of prolapse

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic hysterectomy
Description: Laparoscopic hysterectomy through key hole surgery through small incisions of the abdomen
Study: NCT03150394

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GASTRUS
Description: Gastrus will be given from the first day of eradication treatment to completion after 30 days of treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo will be given from the first day of eradication treatment to completion after 30 days of treatment
Study: NCT02036671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The FLEX System will be used to percutaneously create a fistula in CKD patients who require hemodialysis vascular access
Study: NCT03380104

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intradural Spinal Cord Stimulation
Description: The device will be placed percutaneously at the lumbar spine at L2-3 or L3-4 level into the intrathecal CSF space and advanced to the T8-10 disc space. After positioning of the intrathecal lead, the stimulation catheter will be run through a standardized experimental algorithm consisting on various frequencies.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Administration of Questionnaires
Description: Subjects will be administered questionnaires to evaluate pain, quality of life, and global function prior the study, at 1 hour after the completion of the study, and at 4 day follow-up appointment.
Study: NCT01704001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART-123
Description: 380 U/kg/day or 130 U/kg/day(Subjects with severe renal impairment) for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART-123
Description: 380 U/kg/day or 130 U/kg/day(Subjects with severe renal impairment) for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART-123
Description: 380 U/kg/day or 130 U/kg/day(Subjects with severe renal impairment) for 6 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ART-123
Description: 380 U/kg/day or 130 U/kg/day(Subjects with severe renal impairment) for 6 days
Study: NCT03662113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: 5ml Domperidone prior to VCE

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: water
Description: 5ml water prior to VCE
Study: NCT03039491

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine 23 valent
Description: This is the pneumococcal vaccine consisting of the capsular polysaccharides of 23 serotypes of Streptococcus pneumoniae

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine 23 valent
Description: This is the pneumococcal vaccine consisting of the capsular polysaccharides of 23 serotypes of Streptococcus pneumoniae

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine 23 valent
Description: This is the pneumococcal vaccine consisting of the capsular polysaccharides of 23 serotypes of Streptococcus pneumoniae

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine 23 valent
Description: This is the pneumococcal vaccine consisting of the capsular polysaccharides of 23 serotypes of Streptococcus pneumoniae
Study: NCT04515628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branebrutinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branebrutinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Branebrutinib
Description: Specified dose on specified days
Study: NCT05993520

Intervention type: OTHER
Intervention: Assessment
Description: Between June 2020 and June 2023, 36 volunteer participants aged 18 and above, who were receiving treatment in the Department of Chest Diseases at Istanbul University, Istanbul Faculty of Medicine, and met the inclusion criteria, were included in the project. Participants' respiratory function tests, respiratory muscle functions, dyspnea levels, cough, sleep quality, peripheral muscle strength, quality of life, exercise capacity, and fatigue levels were evaluated.
Study: NCT00239681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Oral

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT01653249

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine consisting of four HPV-16 E6 peptides in combination with Candin®
Study: NCT00688077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcitonin
Description: Calcitonin 200 IU/ml, single subcutaneous injection, experimental group

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 0,9 % 1ml, single subcutaneous injection, placebo group
Study: NCT01293799

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow-up of PD patients´ theoretical and practical skills
Description: Testing of patients knowledge and retraining if needed
Study: NCT00103272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study: NCT04891471

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic RadioTherapy
Description: To treat only brain metastasis identified through Magnetic Resonance imaging by means of stereotactic radiotherapy (experimental intervention) to determine if sparing of clinically uninvolved brain implies a better neurocognitive performance, quality of life and level of autonomy in activities of daily living respect to Whole Brain Irradiation (active comparator).

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole Brain Irradiation
Description: To irradiate the entire brain, site of at least 5 parenchymal metastasis.
Study: NCT02085902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Study: NCT02230306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: 60mg once a day; will be taken on days 1-21 of each 28 day treatment cycle; will be taken in combination with Vemurafenib;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: 960mg twice a day; 28 day treatment cycle; will be taken in combination with Cobimetinib;
Study: NCT02447276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02790112

Intervention type: OTHER
Group type: OTHER
Intervention: GnRHas
Description: Influence of early adiposity rebound, genetic polymorphisms and GnRHa treatment on long-term outcome of treated and untreated girls with idiopathic central precocious compared to a control group.~puberty.

Intervention type: OTHER
Group type: OTHER
Intervention: GnRHas
Description: Influence of early adiposity rebound, genetic polymorphisms and GnRHa treatment on long-term outcome of treated and untreated girls with idiopathic central precocious compared to a control group.~puberty.

Intervention type: OTHER
Group type: OTHER
Intervention: GnRHas
Description: Influence of early adiposity rebound, genetic polymorphisms and GnRHa treatment on long-term outcome of treated and untreated girls with idiopathic central precocious compared to a control group.~puberty.
Study: NCT04848376

Intervention type: DEVICE
Intervention: (1) SmartLoc (2) SmartLoc Evo (3) Winloc(4) Vigor PEEK Cervical Disc Spacer (5) Combo C (6) Polymer Lumbar Disc Spacer (7) X'Plo (8) Rainboo (9) Combo L
Description: As long as there are patients using the above device, conduct questionnaire interview.
Study: NCT03975296

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: preoperative single-shot TMQLB
Description: The patient is placed in the lateral position. The curved probe of Ultrasound Scanner is used for scan and located vertical to the iliac crest at the posterior axillary line to find the Shamrock sign. The 22-G needle is then inserted in plane and directed to the QL muscle. After the proper position of the needle tip between the psoas major muscle and the quadratus lumborum muscle is confirmed, 0. 6 ml/kg 0.5% ropivacaine is injected into the interfascial plane.~Followed by IPCA in the first 48h after surgery: morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: preoperative single-shot TPVB
Description: The patient is placed in the lateral position, the spinous processes of T10 are identified and marks are made 2cm lateral to the spinous processes. The curve probe of ultrasound scanner is placed transversally at the mark to identify the paravertebral space. Then a 22-G needle is inserted in-plane from lateral to medial and advanced until the tip reached the paravertebral space surrounded by the parietal pleura and the superior costotransverse ligament. 0.4 ml/kg 0.5% ropivacaine is injected into the paravertebral space of T10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patient controlled intravenous analgesia(PCIA)
Description: at the end of surgery, patient is administered a PCIA with morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: patient controlled intravenous analgesia(PCIA)
Description: at the end of surgery, patient is administered a PCIA with morphine boluses: 1.5-2 mg, lockout time :10 min, 1h limitation: 6-8 mg morphine.
Study: NCT01800539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Education Model (PEM)
Description: Providers will be trained to use evidence-based practices for early intervention service delivery in the Autism Spectrum Disorder population.
Study: NCT01913626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive group therapy
Description: the cognitive group therapy is composed of eight meetings including information about memory processes, learning and practicing tools and strategies to improve cognition and memory.
Study: NCT03638258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast Cream 0.3%
Description: Applied once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast Cream 0.15%
Description: Applied once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Applied once daily for 12 weeks
Study: NCT02168478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neo-Synalar Cream
Description: Approximately 0.2 g of test material is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Lauryl Sulfate Aqueous Solution (0.40%)
Description: Approximately 0.2 ml of the positive , 0.40% aqueous solution of sodium lauryl sulfate is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline
Description: Saline is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
Study: NCT03793322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine-Green(ICG)
Description: ICG was administered intravenously 24 hours before the operation , or directly into the portal vein branches supplying the tumor-bearing hepatic segment, after puncturing of the target segments under intraoperative ultrasonography guidance.
Study: NCT01174498

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cerbomed t-VNS® transcutaneous stimulation
Description: Subjects experience a transcutaneous, electrical, vagal stimulation with the t-VNS device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: t-VNS Sham stimulation
Description: t-VNS Sham stimulation
Study: NCT01212484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa
Description: The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
Study: NCT04184856

Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI
Description: (Imaging while) performing reward related tasks.

Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI
Description: (Imaging while) performing reward related tasks.

Intervention type: DIAGNOSTIC_TEST
Intervention: fMRI
Description: (Imaging while) performing reward related tasks.
Study: NCT03830515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microMend
Description: Wound closure product consisting of tan array of tiny metal Microstaples affixed to adhesive backing. The device is the size and shape of a butterfly closure and intended for closure of skin wounds.
Study: NCT04087070

Intervention type: DEVICE
Intervention: Biosignal measurements
Description: Following parameters will be measured by non-invasive electrocardiogram (ECG), photoplethysmograph (PPG), and an accelerometer on the chest and will be used to estimate the biosignal derived blood pressure.~1. PAT(time between R peak of ECG and beginning of the pulse of PPG)~2. PEP(time between R peak of ECG and peak of accelerometer signal)~3. PTT(PAT-PEP)
Study: NCT01267058

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' combined diphtheria, tetanus, acellular pertussis vaccine
Description: Intramuscular, single dose
Study: NCT03039491

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine 23 valent
Description: This is the pneumococcal vaccine consisting of the capsular polysaccharides of 23 serotypes of Streptococcus pneumoniae

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine 23 valent
Description: This is the pneumococcal vaccine consisting of the capsular polysaccharides of 23 serotypes of Streptococcus pneumoniae

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine 23 valent
Description: This is the pneumococcal vaccine consisting of the capsular polysaccharides of 23 serotypes of Streptococcus pneumoniae

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine 23 valent
Description: This is the pneumococcal vaccine consisting of the capsular polysaccharides of 23 serotypes of Streptococcus pneumoniae

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13 valent conjugated pneumococcal vaccine
Description: This is the pneumococcal vaccine consisting of the capsular polysaccharides of 13 serotypes of Streptococcus pneumoniae conjugated to non-toxic diphtheria carrier protein 197

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13 valent conjugated pneumococcal vaccine
Description: This is the pneumococcal vaccine consisting of the capsular polysaccharides of 13 serotypes of Streptococcus pneumoniae conjugated to non-toxic diphtheria carrier protein 197

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13 valent conjugated pneumococcal vaccine
Description: This is the pneumococcal vaccine consisting of the capsular polysaccharides of 13 serotypes of Streptococcus pneumoniae conjugated to non-toxic diphtheria carrier protein 197

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13 valent conjugated pneumococcal vaccine
Description: This is the pneumococcal vaccine consisting of the capsular polysaccharides of 13 serotypes of Streptococcus pneumoniae conjugated to non-toxic diphtheria carrier protein 197

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13 valent conjugated pneumococcal vaccine
Description: This is the pneumococcal vaccine consisting of the capsular polysaccharides of 13 serotypes of Streptococcus pneumoniae conjugated to non-toxic diphtheria carrier protein 197
Study: NCT02106702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigator enhanced case-management
Description: Patient navigators are non-clinical, paraprofessional peers who are HIV-infected and have lifetime histories of detention and substance abuse. Working with the patient, they facilitate adherence to a comprehensive care plan designed to address clients' multiple risks and needs. Patients have access to Navigator services for one year after study enrollment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Forensic AIDS Project
Description: The Forensics AIDS Project provides primary care to HIV-infected detainees, as well as up to 90 post-release case-management services which include discharge planning.
Study: NCT03182634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Study: NCT02847338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine 5mg and Amlodipine 10mg will be one of the treatments in which patients will receive on the monotherapy arm and on the dual therapy arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: Amlodipine 5mg and Amlodipine 10mg will be one of the treatments in which patients will receive on the monotherapy arm and on the dual therapy arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Lisinopril 10mg and Lisinopril 20mg will be one of the treatments in which patients will receive on the monotherapy arm.~Lisinopril 20mg will be one of the treatments in which patients will receive on the dual therapy arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Lisinopril 10mg and Lisinopril 20mg will be one of the treatments in which patients will receive on the monotherapy arm.~Lisinopril 20mg will be one of the treatments in which patients will receive on the dual therapy arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiloride
Description: Amiloride 10mg will be one of the treatments in which patients will receive on the dual therapy arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlortalidone
Description: Chlortalidone 25mg will be one of the treatments in which patients will receive on the dual therapy arm and monotherapy arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlortalidone
Description: Chlortalidone 25mg will be one of the treatments in which patients will receive on the dual therapy arm and monotherapy arm.